Table 3.
Summary of validated qRT-PCR results
| H0 (unexposed control) | HARS without pancytopenia | HARS with pancytopenia | HARS with vs without pancytopenia | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gene ID | n (17/16) | Mean | Stdev | Min | Max | n (7/12) | Mean | Stdev | Min | Max | FC | ttest/KW | n 3/5)n | Mean | Stdev | Min | Max | FC | ttest/KW | FC | ttest/KW |
| First day after exposure | |||||||||||||||||||||
| C11orf96 | 14 | 18.7 | 1.0 | 17.0 | 20.2 | 5 | 17.0 | 1.1 | 15.9 | 18.4 | 3.3 | 0.005* | 3 | 16.4 | 1.6 | 14.7 | 17.9 | 4.9 | 0.0056* | 1.5 | 0.6 |
| CDCA7L | 17 | 16.2 | 0.8 | 14.5 | 17.5 | 7 | 17.1 | 1.3 | 15.5 | 19.4 | 0.5 | 0.04 | 3 | 18.4 | 1.9 | 17.1 | 20.6 | 0.2 | 0.2 | 0.4 | 0.2 |
| GBP2 | 15 | 16.8 | 1.3 | 14.7 | 19.0 | 5 | 17.7 | 1.4 | 15.7 | 19.6 | 0.5 | 0.2 | 3 | 18.4 | 1.0 | 17.4 | 19.2 | 0.3 | 0.05 | 0.6 | 0.5 |
| GLUL | 15 | 9.9 | 0.7 | 8.7 | 11.1 | 5 | 8.5 | 0.5 | 7.6 | 9.0 | 2.6 | 0.001* | 3 | 8.2 | 0.5 | 7.8 | 8.8 | 3.2 | 0.002* | 1.2 | 0.5 |
| HERC5 | 17 | 16.7 | 1.1 | 15.1 | 18.5 | 7 | 17.9 | 1.8 | 16.0 | 21.2 | 0.5 | 0.2 | 3 | 18.5 | 0.5 | 18.0 | 18.9 | 0.3 | 0.02 | 0.6 | 0.6 |
| HMHA1 | 15 | 14.6 | 0.5 | 13.8 | 15.5 | 5 | 14.3 | 0.1 | 14.2 | 14.5 | 1.3 | 0.02 | 3 | 14.3 | 0.3 | 14.1 | 14.7 | 1.3 | 0.3 | 1.0 | 0.9 |
| PPP3CC | 17 | 14.5 | 0.5 | 13.2 | 15.2 | 7 | 15.2 | 0.6 | 14.4 | 16.1 | 0.6 | 0.008 | 3 | 15.4 | 0.4 | 15.0 | 15.8 | 0.5 | 0.01 | 0.9 | 0.7 |
| TIMM10B | 16 | 16.2 | 0.5 | 15.2 | 17.2 | 6 | 16.9 | 0.7 | 16.0 | 18.2 | 0.6 | 0.02 | 3 | 17.1 | 0.5 | 16.5 | 17.6 | 0.5 | 0.01 | 0.9 | 0.7 |
| TM4SF19 | 5 | 19.7 | 0.7 | 18.6 | 20.4 | 6 | 17.3 | 1.1 | 15.5 | 18.3 | 5.3 | 0.002* | 2 | 16.5 | 1.1 | 15.7 | 17.3 | 9.4 | 0.005* | 1.8 | 0.4 |
| miR-124 | 9 | 18.9 | 0.8 | 17.1 | 19.8 | 9 | 19.4 | 0.3 | 18.9 | 19.8 | 0.7 | 0.09 | 3 | 18.6 | 0.2 | 18.3 | 18.8 | 1.2 | 0.6 | 1.7 | 0.002* |
| miR-146a | 16 | 13.1 | 0.6 | 12.2 | 14.2 | 11 | 14.5 | 0.5 | 13.7 | 15.7 | 0.4 | <0.0001* | 4 | 14.0 | 0.3 | 13.7 | 14.4 | 0.5 | 0.0076* | 1.4 | 0.1 |
| miR-29c | 15 | 18.1 | 0.9 | 16.2 | 19.2 | 10 | 18.8 | 0.9 | 17.7 | 19.8 | 0.6 | 0.07 | 5 | 17.6 | 1.0 | 16.0 | 18.5 | 1.4 | 0.3 | 2.3 | 0.03 |
| miR-378 | 16 | 10.9 | 0.8 | 9.7 | 12.8 | 10 | 11.3 | 1.3 | 9.1 | 13.8 | 0.7 | 0.3 | 5 | 10.4 | 0.3 | 9.8 | 10.7 | 1.4 | 0.2 | 1.9 | 0.05 |
| miR-574-3p | 16 | 11.6 | 0.6 | 10.6 | 12.5 | 11 | 11.4 | 0.3 | 10.9 | 11.7 | 1.1 | 0.9 | 4 | 10.5 | 0.6 | 9.8 | 11.2 | 2.1 | 0.003* | 2.0 | 0.009 |
| rno-miR-7# | 16 | 14.0 | 0.9 | 12.6 | 15.3 | 10 | 14.6 | 0.6 | 13.5 | 15.6 | 0.7 | 0.1 | 5 | 13.2 | 0.8 | 12.1 | 14.0 | 1.7 | 0.1 | 2.6 | 0.003* |
| Second day after exposure | |||||||||||||||||||||
| CDCA7L | 17 | 16.2 | 0.8 | 14.5 | 17.5 | 6 | 17.7 | 1.3 | 15.6 | 19.1 | 0.3 | 0.002* | 2 | 18.9 | 0.4 | 18.6 | 19.1 | 0.2 | 0.0002* | 0.5 | 0.3 |
| PPP3CC | 17 | 14.5 | 0.5 | 13.2 | 15.2 | 6 | 15.6 | 0.6 | 14.7 | 16.2 | 0.5 | 0.0004* | 2 | 15.6 | 0.4 | 15.4 | 15.9 | 0.5 | 0.01* | 1.0 | 1.0 |
| miR-584 | 16 | 16.1 | 0.7 | 14.8 | 17.2 | 8 | 17.3 | 0.7 | 16.2 | 18.4 | 0.4 | 0.0002* | 4 | 16.8 | 0.4 | 16.4 | 17.2 | 0.6 | 0.06 | 1.5 | 0.2 |
| miR-720 | 16 | 6.5 | 0.6 | 5.4 | 8.0 | 11 | 7.4 | 0.9 | 5.7 | 8.7 | 0.6 | 0.01* | 4 | 6.7 | 0.4 | 6.2 | 7.0 | 0.9 | 0.6 | 1.5 | 0.2 |
| miR-133a | 16 | 16.7 | 1.3 | 14.6 | 19.3 | 10 | 16.3 | 1.8 | 13.1 | 18.5 | 1.3 | 0.6 | 5 | 14.3 | 1.0 | 12.6 | 15.2 | 5.1 | 0.002* | 4.1 | 0.04 |
The table summarizes validated qRT-PCR results (normalized threshold cycle [CT] values) of candidate genes from stage I examined in H0 (day 0 after exposure) and in HARS without and with pancytopenia on days 1 and 2 after radiation exposure. Descriptive statistics reflect the distribution and the fold change (FC) difference among genes differentially expressed relative to H0 as the reference and between both HARS groups in order to compare discrimination between HARS without and with pancytopenia. Numbers in parenthesis for columns entitled n reflect the number of sample where gene expression measurements could be successfully performed. The first and the second number in parenthesis provide the total sample size used for mRNA and miRNA measurements, respectively. The numbers shown per gene can be smaller compared to the total number of samples examined per group (see Table 1). Where applicable, either the t test (ttest) or the Kruskal-Wallis (KW) test was performed for group comparisons. The p values corrected for multiple comparisons (Bonferroni) are marked with an asterisk when they reach values such as p < 0.006 (p = 0.05/9 genes/hypothesis) and p < 0.008 (p = 0.05/6 genes/hypothesis) for mRNA and miRNAs after first day and p < 0.025 (p = 0.05/2 genes/hypothesis) and p < 0.017 (p = 0.05/3 genes/hypothesis) for mRNA and miRNAs after the second day of exposure